Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
McKinsey
Medtronic
McKesson
Fish and Richardson
Queensland Health
Cerilliant
Merck

Generated: June 20, 2018

DrugPatentWatch Database Preview

RAPAFLO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Rapaflo, and when can generic versions of Rapaflo launch?

Rapaflo is a drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in four countries.

The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the silodosin profile page.
Drug patent expirations by year for RAPAFLO
Pharmacology for RAPAFLO
Synonyms for RAPAFLO
( C)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide
(_)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide
(-)-1-(3-Hydroxypropyl)-5-((2R)-2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)-2,3-dihydro-1H-indole-7-carboxamide
(R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide
(R)-1-(3-Hydroxypropyl)-5-[2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]indoline-7-carboxamide
(R)-5-[2-[[2-[2-(2,2,2-trifluoro-ethoxy)phenoxy]ethyl]amino]propyl]-1-(3-hydroxypropyl)-2,3-dihydro-1H-indole-7-carboxamide
1-(3-Hydroxy-propyl)-5-((R)-2-{2-[2-(2,2,2-trifluoro-ethoxy)-phenoxy]-ethylamino}-propyl)-2,3-dihydro-1H-indole-7-carboxylic acid amide
1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]-ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide
1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]indoline-7-carboxamide
1-(3-oxidanylpropyl)-5-[(2R)-2-[2-[2-[2,2,2-tris(fluoranyl)ethoxy]phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
160970-54-7
160970-64-9
1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-
2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide
970S649
A810210
AB0009977
ABP000202
AC-22605
AC1NSM20
AK163125
AKOS005145899
AM20090780
AN-927
API0006406
BDBM50160154
BS-1011
C25H32F3N3O4
CCG-221202
CHEBI:135929
CHEMBL24778
CS-0284
CS0060
CUZ39LUY82
D01965
D0U0VU
DB-064382
DB06207
DTXSID40167045
EBD33557
FT-0674584
FT-0687491
GTPL493
HE070347
HY-10122
I14-33112
I14-8796
KAD 3213
KAD-3213
KAD-3213, KMD-3213
KB-60443
KMD 3213
KMD-3213
KMD3213
KSO-0400
MFCD00930170
MLS006010022
MolPort-006-167-837
PNCPYILNMDWPEY-QGZVFWFLSA-N
Q-102517
Rapaflo (TN)
Rapflo
RL02066
s1613
SC-22125
SCHEMBL136973
silodoshin
Silodosin
Silodosin (JP17/INN)
Silodosin [INN:BAN]
Silodosin-d6
Silodosin(Rapaflo)/KAD 3213,KMD 3213
Silodyx
SMR004701206
SR-01000944157
SR-01000944157-1
UNII-CUZ39LUY82
Urief
Urief (TN)
Urorec
W-5225
ZINC3806063

US Patents and Regulatory Information for RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RAPAFLO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for RAPAFLO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/031 United Kingdom ➤ Try a Free Trial PRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
C0036 France ➤ Try a Free Trial PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129
90028-0.L Sweden ➤ Try a Free Trial PRODUCT NAME: SILODOSIN ELLER FARMACEUTISKA GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/09/607/001-014 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-01-29" SEGODKNR="EU/1/09/607/001-014 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-01-29" FLAG="L" SPCNR="1090028-0" 20100129
00454 Netherlands ➤ Try a Free Trial PRODUCT NAME: SILODOSIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/607/001-014EU/1/09/608/001-014 2010290129
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Merck
Daiichi Sankyo
Argus Health
QuintilesIMS
Mallinckrodt
Fuji
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.